Open Calls for Input and Feedback
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Therapeutic Area: Cystic fibrosis, F508del CFTR mutation, 6 years and older
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation
Spinraza (nusinersen)
Therapeutic Area: Spinal Muscular Atrophy
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation
Firdapse (amifampridine phosphate)
Therapeutic Area: Lambert-Eaton Myasthenic Syndrome, adults
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation
Vyndaqel (tafamidis)
Therapeutic Area: Transthyretin-mediated amyloidosis
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation
HyQvia (immune globulin human and recombinant human hyaluronidase)
Therapeutic Area: Humoral immunodeficiency
Draft recommendations posted for stakeholder feedback: May 19, 2022
End of feedback period: June 3, 2022
Draft Recommendation
Open Calls for Patient and Clinician Input